[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.236.145.124. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 237
Citations 0
Comment & Response
December 2018

Notice of Retraction and Replacement: Roscher et al. Validating 4 Staging Systems for Cutaneous Squamous Cell Carcinoma Using Population-Based Data: A Nested Case-Control Study. JAMA Dermatol. 2018;154(4):428-434.

Author Affiliations
  • 1Department of Dermatology, Oslo University Hospital, Oslo, Norway
  • 2Oslo Centre for Biostatistics and Epidemiology, Oslo, Norway
  • 3The Cancer Registry of Norway, Norway
  • 4Department of Pathology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway
  • 5Research Department, The Cancer Registry of Norway, Majorstuen, Oslo, Norway
JAMA Dermatol. 2018;154(12):1488-1489. doi:10.1001/jamadermatol.2018.4023

To the Editor In an Original Investigation titled “Validating 4 Staging Systems for Cutaneous Squamous Cell Carcinoma Using Population-Based Data: A Nested Case-Control Study,”1 published in the April issue of JAMA Dermatology, we present results of a population-based, nested case-control study assessing the usefulness and validity of 4 staging systems for cutaneous squamous cell carcinoma (cSCC) in nonselected patients. In this study with 184 patients drawn from a nationwide cohort of 6721 patients with cSCC, we categorized patients with or without metastasis based on available information on risk factors. We realize that some patients potentially could have been categorized in a higher risk category if more data on variables necessary for accurate staging had been available, as pointed out by concerned readers of JAMA Dermatology.2

×